news
Competition and Markets Authority investigating AstraZeneca’s Alexion acquisition
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
List view / Grid view
UK Competition and Markets Authority (CMA)
news
International trade officials to review impact of pharma mergers
The Federal Trade Commission will work with international regulators to review the effects of pharma mergers and update approaches to analysing them.
article
Life sciences M&A activity during the global pandemic
COVID-19 has severely disrupted the lives of many people around the world. In this article, corporate partner Theo Godfrey and competition partner Russell Hoare from the life sciences team at law firm CMS Cameron McKenna Nabarro Olswang LLP consider some issues related to COVID-19 that have impacted life sciences merger…
news
UK CMA disqualifies pharma company director after breaking competition law
A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
news
CMA launches COVID-19 taskforce to combat drug price hikes
In the UK, the CMA has announced it will establish a taskforce to handle businesses that exploit the COVID-19 outbreak and inflate drug prices.
news
CMA levels over £3.4m in fines for competition law breaches
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
news
EU court rules GSK committed ‘pay-for-delay’ in paroxetine case
The Competition and Markets Authority (CMA) announced the EU Court of Justice agreed that GSK had paid to delay other competitors entering the UK paroxetine generics market.
news
CMA accuses three pharma companies of illegal market agreement
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
